{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:27:10Z","timestamp":1721780830786},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,23]]},"DOI":"10.7759\/cureus.65200","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T15:41:35Z","timestamp":1721749295000},"source":"Crossref","is-referenced-by-count":0,"title":["A Neuroendocrine Tumor of Unknown Primary Origin: A Case Report and Review of the Literature"],"prefix":"10.7759","author":[{"given":"John","family":"Patresan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harsh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2017.09.002","article-title":"Nothing but NET: a review of neuroendocrine tumors and carcinomas","volume":"19","author":"Oronsky B","year":"2017","unstructured":"Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017, 19:991-1002. 10.1016\/j.neo.2017.09.002","journal-title":"Neoplasia"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7186","article-title":"Carcinoid syndrome: a review","volume":"12","author":"Gade AK","year":"2020","unstructured":"Gade AK, Olariu E, Douthit NT. Carcinoid syndrome: a review. Cureus. 2020, 12:e7186. 10.7759\/cureus.7186","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.377","article-title":"Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours","volume":"115","author":"Childs A","year":"2016","unstructured":"Childs A, Vesely C, Ensell L, et al.. Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours. Br J Cancer. 2016, 115:1540-7. 10.1038\/bjc.2016.377","journal-title":"Br J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2014.216","article-title":"Neuroendocrine tumors of unknown primary: is the primary site really not known?","volume":"149","author":"Bergsland EK","year":"2014","unstructured":"Bergsland EK, Nakakura EK. Neuroendocrine tumors of unknown primary: is the primary site really not known?. JAMA Surg. 2014, 149:889-90. 10.1001\/jamasurg.2014.216","journal-title":"JAMA Surg"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.160771","article-title":"Principles of diagnosis and management of neuroendocrine tumours","volume":"189","author":"Raphael MJ","year":"2017","unstructured":"Raphael MJ, Chan DL, Law C, Singh S. Principles of diagnosis and management of neuroendocrine tumours. Can Med Assoc J. 2017, 189:E398-404. 10.1503\/cmaj.160771","journal-title":"Can Med Assoc J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-008-0769-2","article-title":"Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours","volume":"35","author":"Ambrosini V","year":"2008","unstructured":"Ambrosini V, Tomassetti P, Castellucci P, et al.. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008, 35:1431-8. 10.1007\/s00259-008-0769-2","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000504370","article-title":"Diagnostic approaches to neuroendocrine neoplasms of unknown primary site","volume":"110","author":"Berner AM","year":"2020","unstructured":"Berner AM, Pipinikas C, Ryan A, et al.. Diagnostic approaches to neuroendocrine neoplasms of unknown primary site. Neuroendocrinology. 2020, 110:563-73. 10.1159\/000504370","journal-title":"Neuroendocrinology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-018-0168-2","article-title":"Identification and characterization of myocardial metastases in neuroendocrine tumor patients using 68Ga-DOTATATE PET-CT","volume":"18","author":"Kunz WG","year":"2018","unstructured":"Kunz WG, Eschbach RS, Stahl R, et al.. Identification and characterization of myocardial metastases in neuroendocrine tumor patients using 68Ga-DOTATATE PET-CT. Cancer Imaging. 2018, 18:34. 10.1186\/s40644-018-0168-2","journal-title":"Cancer Imaging"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.596921","article-title":"Case report: neuroendocrine tumor with cardiac metastasis","volume":"7","author":"Kinney RE","year":"2020","unstructured":"Kinney RE, Decker R, Sundlof D, Rizvi MA, Schadler K. Case report: neuroendocrine tumor with cardiac metastasis. Front Cardiovasc Med. 2020, 7:596921. 10.3389\/fcvm.2020.596921","journal-title":"Front Cardiovasc Med"},{"key":"ref10","article-title":"Primary high-grade neuroendocrine carcinoma of the heart","volume":"40","author":"Guajardo-Salinas GE","year":"2013","unstructured":"Guajardo-Salinas GE, Anaya-Ayala JE, Rice DC, Moran CA, Reardon MJ. Primary high-grade neuroendocrine carcinoma of the heart. Tex Heart Inst J. 2013, 40:71-4.","journal-title":"Tex Heart Inst J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i15.2640","article-title":"Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies?","volume":"23","author":"Cavalcoli F","year":"2017","unstructured":"Cavalcoli F, Rausa E, Conte D, Nicolini AF, Massironi S. Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies?. World J Gastroenterol. 2017, 23:2640-50. 10.3748\/wjg.v23.i15.2640","journal-title":"World J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5104082","article-title":"Efficacy and prognostic factors for Y-90 radioembolization (Y-90) in metastatic neuroendocrine tumors with liver metastases","volume":"2020","author":"Tsang ES","year":"2020","unstructured":"Tsang ES, Loree JM, Davies JM, et al.. Efficacy and prognostic factors for Y-90 radioembolization (Y-90) in metastatic neuroendocrine tumors with liver metastases. Can J Gastroenterol Hepatol. 2020, 2020:5104082. 10.1155\/2020\/5104082","journal-title":"Can J Gastroenterol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/2042018818804698","article-title":"Current best practice in the management of neuroendocrine tumors","volume":"10","author":"Tsoli M","year":"2019","unstructured":"Tsoli M, Chatzellis E, Koumarianou A, Kolomodi D, Kaltsas G. Current best practice in the management of neuroendocrine tumors. Ther Adv Endocrinol Metab. 2019, 10:2042018818804698. 10.1177\/2042018818804698","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg J","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, et al.. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017, 376:125-35. 10.1056\/NEJMoa1607427","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i26.4174","article-title":"Progress in immunotherapy for neuroendocrine neoplasm of the digestive system","volume":"29","author":"Pan WX","year":"2023","unstructured":"Pan WX, Zhang XM, Hao SL, Han W. Progress in immunotherapy for neuroendocrine neoplasm of the digestive system. World J Gastroenterol. 2023, 29:4174-85. 10.3748\/wjg.v29.i26.4174","journal-title":"World J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-017-9437-9","article-title":"Management of neuroendocrine tumors of unknown primary","volume":"18","author":"Alexandraki K","year":"2017","unstructured":"Alexandraki K, Angelousi A, Boutzios G, Kyriakopoulos G, Rontogianni D, Kaltsas G. Management of neuroendocrine tumors of unknown primary. Rev Endocr Metab Disord. 2017, 18:423-31. 10.1007\/s11154-017-9437-9","journal-title":"Rev Endocr Metab Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/160908-a-neuroendocrine-tumor-of-unknown-primary-origin-a-case-report-and-review-of-the-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T15:41:39Z","timestamp":1721749299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/160908-a-neuroendocrine-tumor-of-unknown-primary-origin-a-case-report-and-review-of-the-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.65200","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,23]]}}}